Sentences with phrase «antimalarial drug resistance»

His primary focus is on developing new statistical methods to understand the evolution of these parasites at a population level, in order to shed light on the underlying genetics of antimalarial drug resistance.

Working as a global community, we can now build on this technique to identify hotspots of antimalarial drug resistance around the world and contain them effectively.»

It also provides an important insight into why antimalarial drug resistance (previously to chloroquine and antifols, and now to artemisinin) arises in Western Cambodia,» says Professor Nicholas White of Mahidol University in Bangkok, Thailand and Oxford University.

This release comes at a time when the latest wave of antimalarial drug resistance, including the frontline drug, artemisinin, is threatening gains made against malaria.

The meeting explored the genomic epidemiology of the host, vector and parasite, highlighting the practical relevance of this research to global health, including antimalarial drug resistance, insecticide resistance, vaccine design, and mechanisms of protective immunity.

«Study first to explain type of antimalarial drug resistance.»

Not exact matches

«This is an excellent evaluation of an exciting new series of antimalarial drugs,» says Nick White of the Mahidol University in Bangkok, Thailand, a country where resistance is developing fast to artemisinins, the most potent class of antimalarial drugs now in use.

Resistance to the world's most effective antimalarial drug, artemisinin, has developed in South - East Asia, with fears it will soon reach Africa.

While several antimalarial drugs have successfully treated the disease, in some regions they no longer work due to drug resistance.

The findings suggest that other antimalarial medications that target maternally inherited organelles in the parasite may also have limited drug resistance.

At the ASTMH meeting, scientists launched the Worldwide Antimalarial Resistance Network (WWARN), a global database that will collect information on resistance in vivo and in vitro, drug levels in patients» blood, and moleculaResistance Network (WWARN), a global database that will collect information on resistance in vivo and in vitro, drug levels in patients» blood, and molecularesistance in vivo and in vitro, drug levels in patients» blood, and molecular markers.

Current antimalarial drugs are becoming less effective as the parasite develops resistance to the drugs, making the search for new targets that can kill all species of malaria critical.

In the early 2000s, the malaria parasite Plasmodium falciparum developed resistance to the commonly used antimalarial drug chloroquine.

«Over 400,000 people die of malaria each year, and resistance to common antimalarial drugs is growing,» says Professor Mike Blackman, Group Leader at the Francis Crick Institute, who led the research.

In an effort to keep artemisinin resistance at bay, the World Health Organization (WHO) has recommended artemisinin combination therapies (ACTs)-- uniting artemisinin derivatives with bygone antimalarial drugs — as the preferred front - line treatment.

«As drug resistance is a major problem for malaria control and eradication, it is critical that that we continue to develop new antimalarials that act against previously unexploited targets in the parasite to keep priming the drug pipeline.»

Diversifying the antimalarial arsenal could also extend the lifespan of existing drugs, since relying less heavily on our most commonly used weapons gives the parasite fewer opportunities to develop resistance, Derbyshire said.

Resistance to vital antimalarial drugs called artemisinins has spread across Burma to the Indian border.

Working closely with more than 200 data contributors, WWARN is able to use this powerful resource to perform pooled analyses that uncover new insights into the emergence and spread of malaria drug resistance, including evaluating the efficacy of antimalarial combination therapies (ACTs), and examining whether known molecular markers can predict clinical outcomes.

The most comprehensive genetic study of malaria parasites in Southeast Asia has shown that resistance to antimalarial drugs was under - reported for years in Cambodia.

A worldwide collaboration of researchers has shown that resistance to the frontline antimalarial drug — artemisinin — can be identified by surveying the genomes of parasite populations.

This is an impressive achievement but these gains are threatened by emerging resistance to the frontline antimalarial drug, artemisinin.

Each time a new antimalarial drug has been introduced, the parasites have evolved resistance to it.

Methods: Sixty - eight parasites isolates with in vivo clearance data were obtained from two Tracking Resistance to Artemisinin Collaboration study sites in Cambodia, culture - adapted, and genotyped for pfkelch13 and other mutations including pfmdr1 copy number; and the RSA0 - 3h survival rates and response to antimalarial drugs in vitro were measured for 36 of these isolates.